If you have trouble viewing the newsletter, please click here.

Dear ESOP-members!

Newsletter July 2017 meets readers consisting oncology pharmacists and enthusiasts. This newsletter includes an article about 10th Masterclass in Oncology Pharmacy which was held in Thesselaniki and a survey's results with graphical figures regarding the trainings. Also in this newsletter you will get articles about 41st Brno Oncology Days, Valencia and 1st Pharmacist day at the 14th International Symposium on Myelodysplastic Syndromes within 31st Conference for Non -medical Healthcare Professionals, Czech National Oncology Congress.

We wish you good readings ...

Yours, Eda Gedikoglu

Chair of Publication

10TH MASTERCLASS IN ONCOLOGY PHARMACY

12. - 16. December 2016, Thessaloniki/ Greece

ESOP Community AT ITS BEST!

The temporary postponement of the 10thMasterClass in Oncology Pharmacy was an inauspicious start of the event. However, the obstacles were overcome, the event was re-organized and the 10th MasterClass was launched on the 12th of December, at the great city of Thessaloniki (Greece).

ESOP President Klaus Meier induced the participants to the principals of MasterClass and then MasterClass officially started. The first acquaintanceships between the participants gave way to greater interactions. As the time moved on, the friendly atmosphere was escalated and followed by well co-operations and productive discussions in lectures and workshops.

Graph 1: Educational level

MasterClasse's lectures and workshops covered a large range of topics about antineoplastic drugs, safe handling of cytotoxics and the Cytotoxic Drugs Preparation Unit. Some of the most important points are summarized below:

  • The significance of installing a perfect collaboration with other health care professionals in order to achieve the best outcome for the patient.
  • The significance of counseling the patients regarding their medication side effects and interactions in order to optimize their drug therapy.
  • Diminution of medical risks.
  • The different devices used for the preparation of antineoplastic drugs.
  • The safe handling of cytotoxic drugs, management of cytotoxic spills and waste disposal, based on Quapos 5 guidelines.
  • The pharmacological analysis of antineoplastic drugs (mechanism of action, side effects, etc)
  • The risk of extravasation (extravasation types, antidotes and avoidance measures).
  • Oral chemotherapy as a changing trend; its advantages and challenges.
  • Quality need for oncology pharmacy, how to write standard operating procedures (SOP).
  • Method of analysis and stability issues of anticancer drugs, need for standardized analytical protocols and stability data in real hospital situations.

At the end of the 10th MasterClass, a survey was performed among the participants. The purpose of this evaluation was to improve ESOP MasterClass programmes and find out how to contribute more to our colleagues' daily practice. The evaluation form, which was filled in by 23 (out of 36) participants, revealed interesting points. More specifically, 77% of the participants who answered the survey, found the educational level of the MasterClass quite appropriate (Graph 1)

The fact that the great majority of the respondents (21 out of 23) believe that the scientific lectures were freed from promotional material, highlights the unbiased background of the MasterClass.

As far as the dissemination of the MasterClass is concerned, approximately 48% of the respondents found it out through personal recommendation. In addition, the news of the event was spread out by ESOP website and ESOP emails (Graph 2).

Graph 2: Sources of MasterClass conduction

Furthermore, the answers on the evaluation form indicate that the participants were quite pleased on the organization and social aspects of the 5-days MasterClass. More specifically, accommodation services, catering, registration process were some of the aspects which were evaluated as excellent or very good (Graph 3).

Graph 3: Organization and Social aspects

Finally, one of the most important parts of the evaluation form was related to the learning outcomes of the MasterClass. As it is presented on Graph 4, participants found the MasterClass well updated, as far as the latest developments on the cytotoxic preparation is concerned. Also, the presented data helped the participants to understand in depth the relevant information regarding cytotoxic drugs, while collaborations at European level were developed. However, it seems like issues regarding the evolution of oncology pharmacy towards clinical pharmacy and patient education must be improved. Overall, the participants were very pleased with the quality of the education offered at the 10th MasterClass.

Graph 4: Goals and Learning outcomes

As far as the most interesting parts of the 10th MasterClass are concerned, the respondents highlighted the spillkit training and device training, the "Aseptic Technique" workshop, the lectures on "Extravasation" and on "Clinical Trials". Also, they seemed to enjoy the exchange of knowledge between different European countries.

However, the comments on weaknesses of the 10th MasterClass were also taken into consideration. More specifically, respondents stated that "The Classification and Mechanism of Action of Antineoplastic Drugs" lecture was one of the must have topics, but its presentation was quite weak. In addition, some lectures were very long and their topics were repeated, thus they could be abbreviated or combined. Furthermore, some lecture notes were not included at the MasterClass book, which was also difficult to use, due to its bound.

In addition, participants, who answered the questionnaire, made suggestions on the next Basic and Intermediate MasterClass. In particular, they recommended more concrete examples about clinical trials, which are in progress. In addition, participants think that a section on alternative methods for countries, which do not have access to top-class equipment, would be very helpful.

Also, they seem to prefer more workshops and practical information to be included on the future MasterClasses.

In general, the vast majority of the respondents (96%) believes that the 10th Materclass was excellent or very good, as it is presented on Graph 5. In conclusion, participants of the 10th MasterClass had a great opportunity to reinforce their knowledge on oncology topics and also to meet new people from all over the world and exchange ideas and experiences. The 10th MasterClass, which took place in Thessaloniki of Greece, was crowned with success!

Next Stop: Lisbon-Portugal!

Reported By: Klio Bourika

Graph 5: Overall Judgment

BOD 2017

41st Brno Oncology Days and the and 31st Conference for Non-medical Healthcare Professionals (41. Brnenské onkologické dny a 31. Konference pro nelékarské pracovníky), Czech National Oncology Congress was held at 26th - 28th April 2017 in Brno, Czech Republic.

The participants of the congress was attended mainly from the Czech Republic and about 10 speakers from another countries. As a special guest of pharmacy, Klaus Meier, president of ESOP, was invited.

The congress was conducted by the participation of more than 2257 attendees including physicians (more than 750), pharmacists (60), nurses, laboratory technicians, biomedical engineers (more than 700), students and patients.

In the block of clinical pharmacy, workshop of pain pharmacology took place. This block was traditionally held with cooperation with CLS JEP (Czech Medical Association of J. E. Purkyne).

Reported by: Michal Budinský

FIRST PHARMACIST DAY AT THE 14TH INTERNATIONAL SYMPOSIUM ON MYELODYSPLASTIC SYNDROMES

3TH-6TH MAY 2017,VALENCIA/SPAIN

The Spanish Society of Hospital Pharmacy (SEFH) and its Oncology Pharmacist Group (GEDEFO) have been invited by the scientific committee to participate in the planning and organization of the First Pharmacist Sessions included in the 14th International Congress of Myelodysplastic Syndromes (MDS) held in Valencia from the 3 to the 6 of May.

The first session reviewed the diagnosis of MDS and the evaluation of response to treatment by Dr. Guillermo Sanz. He highlighted that although some somatic mutations are associated with a worse or better prognosis these mutations have not been incorporated into prognostic index. He pointed out the need for a consensus on the criteria for evaluation of response to new drugs.

The following speakers Dr. Hannah Kershaw and Dr. Garbińe Lizeaga reviewed current available treatments and those under investigation for MDS patients, and they both agreed that there have been few advances to change actual guidelines and the importance of pharmacist's role to improve or optimize management of available treatments.

In the second session, Dr. Raúl Córdoba reviewed the multidisciplinary approach of geriatric assessment in hematologic patients, the tools that help us to assess comorbidities and final treatment decision. Dr. Estela Moreno explained the role of clinical pharmacist in the identification of interactions and polypharmacy, and exposed the key aspects of the deprescription Process in geriatric patients.

Plans for the 6th QuapoS becoming concrete

The Discussion about the way how to present the activities of Oncology Pharmacists started in the early 90th with the first German workshop. In the meantime, the first version of the quapos was adopted by the German members in 1996. In 2000, the second version was adopted, in 2004 the 3rd, 2009 the 4th and finally 2014 the 5th version of the Quapos. The national conferences have been accompanied by voting meetings with the European delegates in Luxembourg, 2001, 2004 and 2008.

In addition, more than 40 colleagues haven written a personal commentary after the common elaboration of the standard. This increased the QuapoS from 20 pages to more than 500 pages.

This year the plans for the 6th quapos has becoming concrete. The QuapoS is scheduled to appear on the ECOP 2018 (October) on a European level. The response to the request for cooperation was extremely good throughout our membership. (29 countries have agreed to submit proposals for amendment). Now all our members are free to inform their national delegates about their proposal as until the end of August these proposals will be collected by the core working team of Kristjan (EST), Kathleen (NL), Ana Margarida (P), Teresa (PL), Magda (DK), Hannelore and Bernhard (D).

We are looking forward receiving your support.

Save the date - upcoming events

3rd EORTC Cancer Survivorship Summit, 1-2 March 2018, Brussels, Belgium

Everywhere in Europe the survival rate of cancer has improved. As of today, there are around 10 million European cancer survivors of which more than a third are of working age.

Although it is no longer a death sentence, preventing survivors cancer

risks remaining a life from resuming a normal life. Research shows a higher unemployment rate in cancer survivors as compared to the cancer-free population. Also, individual testimonies illustrate challenges in obtaining health/life insurance, loans and mortgage.

events.eortc.org/wpmulti/survivorship

Course dedicated to Patients and Caregivers interested in Cancer Clinical Research, 2-3 March 2018, Brussels, Belgium

This course is designed specifically for European patients and/or patient representatives involved in cancer patient advocacy/patient support/patient information. The goal of this course is to provide cancer patient advocates with a stimulating and challenging two-day training experience leading to a much greater understanding of the whole clinical trials process.

events.eortc.org/wpmulti/patientdays/

If you don't want to recieve any further ESOP Newsletters, please click to unsubscribe.